The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving Treatment Outcomes For Malignant Mesothelioma Patients Using Biomarkers.
Funder
National Health and Medical Research Council
Funding Amount
$795,262.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. In this study we will use novel biomarkers to help the diagnosis of mesothelioma and potentially improve treatment options for patients.
Advanced Technologies For Improved Molecular Diagnostic And Prognostic Of Gastrointestinal Cancers
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The aim of this interdisciplinary research is to develop innovative and clinically relevant technologies for improved molecular diagnostic of gastrointestinal cancers. It integrates technological advances in physics, bioengineering and nanoscience with state-of-the-art molecular technologies towards the delivery of both fundamental and translational outcomes. These technologies will be applied to address important fundamental questions such as the role of circulating tumour cells.
Bronchiectasis And Infection With The Human T-lymphotropic Virus 1 Among Indigenous Australians
Funder
National Health and Medical Research Council
Funding Amount
$849,674.00
Summary
The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis ....The Indigenous people of Central Australia have the highest reported prevalence of bronchiectasis in the world. In a recent study, we found infection with Human T -cell Lymphotropic Virus type 1 (HTLV-1) may contribute to the devlopment of bronchiectasis. The present study seeks to confirm this association and to determine whether increased HTLV-1 activity is associated with greater risk. This will require the development of assays that will improve diagnosis and assist in determining prognosis of HTLV infection.Read moreRead less
A Novel One-step Approach In The Early Diagnosis Of Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$102,150.00
Summary
In order to avoid the invasiveness and imprecision of current prostate cancer detection, this programme is directed to developing a non-invasive and repeatable, accurate approach. This research project is designed to optimise retrieval of prostate cells from ejaculate and to compare two methods for profiling selected genetic changes to diagnose prostate cancer. The refinement of techniques, outlined in the application, is essential before proceeding to a clinical trial.
DNA Barcoding Of Pathogenic Fungi As The Basis For The Development Of Novel Standardized Diagnostic Tools
Funder
National Health and Medical Research Council
Funding Amount
$560,398.00
Summary
Fungal infections are increasing and have major health impacts, with a high economic burden. Timely initiation of therapy is the key to improve patient outcomes. However, reliable identification tools for fungal pathogens are lacking. We will use comparative genome analysis to develop unique fungal signatures (DNA barcodes) and establish an online database to allow for rapid identification for diagnosis in the clinical setting and as a quarantine tool for border protection.
The Diagnosis, Biomarker Identification And Measurement Of Drug Efficacy In Mental Illness And Neurological Conditions.
Funder
National Health and Medical Research Council
Funding Amount
$119,050.00
Summary
Globally, 2 billion people suffer from a neuropsychiatric illness. The cost is more than US$2 trillion a year. Hampering early intervention is the current lack of definitive, quantitative techniques for diagnosis and measurement of treatment efficacy. This research will determine whether the disease fingerprints produced by a new technique, EVestG, are diagnostically unique (to schizophrenia, depression and Parkinson's disease) and sensitive to disease progression and treatment response.
SFRP4 As A Novel Diagnostic And Therapeutic Target For Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$137,700.00
Summary
Gastric cancer is a common cancer with poor survival, but is and potentially curable when diagnosed at an early stage. However currently there are no non-invasive markers for the early detection of gastric cancer, and treatments for advanced cancer are limited. Secreted frizzled related protein 4 (SFRP4) is a protein that is thought to play a role in invasion of gastric cancer. This study will investigate the utility SFRP4 as a diagnostic test and possible therapeutic for gastric cancer.
Development Of A Multiplex Assay For The Identification Of Women At Risk Of Preterm Labour.
Funder
National Health and Medical Research Council
Funding Amount
$202,350.00
Summary
Preterm birth (ie birth before the 37th week of gestation) is the most significant problem facing contemporary clinical obstetrics in the developed world and occurs in approximately 5% to 12% of all deliveries. Being born too early is the major cause of perinatal morbidity and mortality. Data from Australia indicate that each year, more than 17,000 babies will be born prematurely. Of these infants, over 10,000 will suffer respiratory complications and about 1300 will die during the first 21 days ....Preterm birth (ie birth before the 37th week of gestation) is the most significant problem facing contemporary clinical obstetrics in the developed world and occurs in approximately 5% to 12% of all deliveries. Being born too early is the major cause of perinatal morbidity and mortality. Data from Australia indicate that each year, more than 17,000 babies will be born prematurely. Of these infants, over 10,000 will suffer respiratory complications and about 1300 will die during the first 21 days of life. The sickest and most premature of these infants require admission to a Neonatal Intensive Care Unit in a tertiary hospital. Aside from the medical implications of premature delivery, there is also a considerable fiscal challenge to society. While treatments for the prevention of labour have improved considerably over the past decade, current screening tests of preterm labour (ie Fetal Fibronectin test) are unreliable and have poor positive predictive values. The principal objective of this project is to develop and deliver a multiplex assay for the prediction and diagnosis of human preterm labour. Through the successful application of our own proteomic discovery programmes using both ovine and human cervico-vaginal fluid samples, we have identified several new protein markers of labour. Having completed this Phase 1 biomarker trial and established proof-of-concept, we are now well positioned to initiate a Phase 2 biomarker trial to determine reliable estimates of assay sensitivity and specificity. This project targets the development of a new diagnostic to meet a recognised market gap. Delivery of such a test will create a new market in pregnancy-based clinical diagnostics and significantly impact on improving health care and quality of life for many preterm babies. Should the project be completed as detailed and mitigate some of the risk of commercial development, it would then be realistic to seek substantial funding from the private sector.Read moreRead less
Implementation Of A New, Inexpensive And High-throughput Matrix Assisted Laser Desorption / Ionization _ Time Of Flight Mass Spectrometry Test For Superior Detection Of Fragile X Syndrome In Targeted Diagnostics And Newborn Population Screening.
Funder
National Health and Medical Research Council
Funding Amount
$254,175.00
Summary
Background: The Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability. There are now a number of treatments for FXS. However, often this disorder is not clearly recognized. We have developed a novel FXS test that could resolve this issue. Our objective is to develop a commercial package that describes suitability of our test for diagnostic use. If successful this could potentially leading to improvement in the prognosis for FXS children through early treatment int ....Background: The Fragile X Syndrome (FXS) is the most common form of inherited intellectual disability. There are now a number of treatments for FXS. However, often this disorder is not clearly recognized. We have developed a novel FXS test that could resolve this issue. Our objective is to develop a commercial package that describes suitability of our test for diagnostic use. If successful this could potentially leading to improvement in the prognosis for FXS children through early treatment intervention.Read moreRead less